CRNX:NSD-Crinetics Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 44.43

Change

+1.06 (+2.44)%

Market Cap

USD 3.45B

Volume

0.84M

Analyst Target

USD 36.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-0.22 (-0.06%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

-7.48 (-0.84%)

USD 106.98B
MRNA Moderna Inc

+1.79 (+1.69%)

USD 38.83B
ARGX argenx NV ADR

+4.20 (+1.14%)

USD 22.08B
BNTX BioNTech SE

+0.50 (+0.58%)

USD 21.93B
GMAB Genmab AS

+0.69 (+2.51%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-0.40 (-0.28%)

USD 18.18B
RPRX Royalty Pharma Plc

-0.11 (-0.39%)

USD 18.18B
BGNE BeiGene Ltd

+5.02 (+3.38%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-1.26 (-1.53%)

USD 16.06B

ETFs Containing CRNX

CURE:AU ETFS S&P Biotech ETF 1.06 % 0.00 %

-1.58 (-3.57%)

USD 0.04B
IWC iShares Micro-Cap ETF 0.00 % 0.60 %

+1.17 (+-3.57%)

USD 0.89B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

+3.79 (+-3.57%)

USD 1.24B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.63 (+-3.57%)

USD 0.10B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+1.27 (+-3.57%)

USD 7.05B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.87% 68% D+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.87% 68% D+ 84% B
Trailing 12 Months  
Capital Gain 178.73% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 178.73% 93% A 96% N/A
Trailing 5 Years  
Capital Gain 95.21% 82% B 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.21% 82% B 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 13.03% 69% C- 74% C
Dividend Return 13.03% 69% C- 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.65% 61% D- 38% F
Risk Adjusted Return 29.19% 82% B 66% D+
Market Capitalization 3.45B 94% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector